Welcome to LookChem.com Sign In|Join Free

CAS

  • or
(S)-tert-butyl 1-(5-fluoropyridin-2-yl)ethylcarbaMate is a carbamic acid derivative with the molecular formula C14H20FN3O2, featuring a fluoropyridine group. It is a carbamate ester known for its potential in the pharmaceutical industry as a building block for synthesizing various pharmaceutical agents. (S)-tert-butyl 1-(5-fluoropyridin-2-yl)ethylcarbaMate's tert-butyl group contributes to its stability and solubility, making it a valuable intermediate in organic synthesis. (S)-tert-butyl 1-(5-fluoropyridin-2-yl)ethylcarbaMate holds significant potential for medicinal and scientific research, particularly in the development of new drugs for the treatment of diseases such as cancer, neurological disorders, and infectious diseases.

905587-16-8 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 905587-16-8 Structure
  • Basic information

    1. Product Name: (S)-tert-butyl 1-(5-fluoropyridin-2-yl)ethylcarbaMate
    2. Synonyms: (S)-tert-butyl 1-(5-fluoropyridin-2-yl)ethylcarbaMate;tert-butyl(S)-(1-(5-fluoropyridin-2-yl)ethyl)carbamate
    3. CAS NO:905587-16-8
    4. Molecular Formula: C12H17FN2O2
    5. Molecular Weight: 240.2739832
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 905587-16-8.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 324.8±32.0 °C(Predicted)
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: 1.115±0.06 g/cm3(Predicted)
    6. Refractive Index: N/A
    7. Storage Temp.: 2-8°C
    8. Solubility: N/A
    9. PKA: 11.26±0.46(Predicted)
    10. CAS DataBase Reference: (S)-tert-butyl 1-(5-fluoropyridin-2-yl)ethylcarbaMate(CAS DataBase Reference)
    11. NIST Chemistry Reference: (S)-tert-butyl 1-(5-fluoropyridin-2-yl)ethylcarbaMate(905587-16-8)
    12. EPA Substance Registry System: (S)-tert-butyl 1-(5-fluoropyridin-2-yl)ethylcarbaMate(905587-16-8)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 905587-16-8(Hazardous Substances Data)

905587-16-8 Usage

Uses

Used in Pharmaceutical Industry:
(S)-tert-butyl 1-(5-fluoropyridin-2-yl)ethylcarbaMate is used as a building block for the synthesis of pharmaceutical agents due to its structural properties that can be incorporated into the development of new drugs.
Used in Drug Development for Cancer Treatment:
In the field of oncology, (S)-tert-butyl 1-(5-fluoropyridin-2-yl)ethylcarbaMate is used as a precursor in the development of new anticancer drugs, potentially targeting various types of cancer.
Used in Drug Development for Neurological Disorders:
(S)-tert-butyl 1-(5-fluoropyridin-2-yl)ethylcarbaMate is also utilized in the research and development of pharmaceuticals aimed at treating neurological disorders, given its potential to interact with specific biological targets relevant to such conditions.
Used in Drug Development for Infectious Diseases:
Furthermore, (S)-tert-butyl 1-(5-fluoropyridin-2-yl)ethylcarbaMate is used in the creation of new drugs intended to combat infectious diseases, possibly due to its ability to interfere with microbial processes or enhance host defense mechanisms.
Used in Organic Synthesis:
Beyond its pharmaceutical applications, (S)-tert-butyl 1-(5-fluoropyridin-2-yl)ethylcarbaMate is used as an intermediate in organic synthesis, taking advantage of its reactivity and the stability conferred by the tert-butyl group.

Check Digit Verification of cas no

The CAS Registry Mumber 905587-16-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,0,5,5,8 and 7 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 905587-16:
(8*9)+(7*0)+(6*5)+(5*5)+(4*8)+(3*7)+(2*1)+(1*6)=188
188 % 10 = 8
So 905587-16-8 is a valid CAS Registry Number.

905587-16-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name tert-butyl N-[(1S)-1-(5-fluoropyridin-2-yl)ethyl]carbamate

1.2 Other means of identification

Product number -
Other names QC-709

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:905587-16-8 SDS

905587-16-8Relevant articles and documents

2-(IMIDAZ0LYLAMIN0)-PYRIDINE DERIVATIVES AND THEIR USE AS JAK KINASE INHIBITORS

-

Page/Page column 65, (2010/04/03)

The present inv ention relates to compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein Ring A is 5- or 6-membered heteroaryl, wherein said 5- or 6-membered heteroaryl is optionally substituted on carbon with one or more R6

CHEMICAL COMPOUNDS 000-1

-

Page/Page column 55, (2009/04/25)

The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer.

Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors

Ioannidis, Stephanos,Lamb, Michelle L.,Davies, Audrey M.,Almeida, Lynsie,Su, Mei,Bebernitz, Geraldine,Ye, Minwei,Bell, Kirsten,Alimzhanov, Marat,Zinda, Michael

scheme or table, p. 6524 - 6528 (2010/05/18)

The design, synthesis and biological evaluation of a series of pyrazol-3-ylamino pyrazines as potent and selective JAK2 kinase inhibitors is reported, along with the pharmacokinetic and pharmacodynamic properties of lead compounds.

PYRAZOLYL-AMINO-SUBSTITUTED PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CANCER

-

, (2008/12/08)

The present invention relates to compounds of Formula (I) and to their pharmaceutical compositions, and to their methods of use. These compounds provide a treatment for myeloproliferative disorders and cancer.

PYRAZOLYL-AMINO-SUBSTITUTED PYRAZINES AND THEIR USE FOR THE TREATMENT OF CANCER

-

, (2008/12/04)

The present invention relates to compounds of Formula (I): and to their pharmaceutical compositions, and to their methods of use. These novel compounds provide a treatment for myeloproliferative disorders and cancer.

5-AMINOPYRAZOL-3-YL-3H-IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER

-

, (2008/12/08)

The present invention relates to compounds of Formula (I) and to their pharmaceutical compositions, and to their methods of use. These novel compounds provide a treatment for myeloproliferative disorders and cancer.

AMINO-THIAZOLYL- PYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER

-

, (2009/01/20)

The present invention relates to compounds of Formula (I): and to their pharmaceutical compositions, and to their methods of use. These compounds provide a treatment for myeloproliferative disorders and cancer.

9- (PYRAZOL- 3 -YL) - 9H- PURINE-2 -AMINE AND 3- (PYRAZ0L-3-YL) -3H-IMIDAZ0 [4, 5-B] PYRIDIN-5-AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER

-

, (2009/01/20)

The present invention relates to compounds of Formula (I): and to their pharmaceutical compositions, and to their methods of use. These compounds provide a treatment for myeloproliferative disorders and cancer.

Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases

Wang, Tao,Lamb, Michelle L.,Scott, David A.,Wang, Haixia,Block, Michael H.,Lyne, Paul D.,Lee, John W.,Davies, Audrey M.,Zhang, Hai-Jun,Zhu, Yanyi,Gu, Fei,Han, Yongxin,Wang, Bin,Mohr, Peter J.,Kaus, Robert J.,Josey, John A.,Hoffmann, Ethan,Thress, Ken,MacIntyre, Terry,Wang, Haiyun,Omer, Charles A.,Yu, Dingwei

experimental part, p. 4672 - 4684 (2009/07/25)

The design, synthesis and biological evaluation of a series of 4-aminopyrazolylpyrimidines as potent Trk kinase inhibitors is reported. High-throughput screening identified a promising hit in the 4- aminopyrazolylpyrimidine chemotype. Initial optimization of the series led to more potent Trk inhibitors. Further optimization using two strategies resulted in significant improvement of physical properties and led to the discovery of 10z (AZ-23), a potent, orally bioavailable Trk A/B inhibitor. The compound offers the potential to test the hypothesis that modulation of Trk activity will be of benefit in the treatment of cancer and other indications in vivo.

CHEMICAL COMPOUNDS

-

, (2010/11/25)

This invention relates to novel compounds having the formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 905587-16-8